celecoxib has been researched along with Carcinoma, Ductal, Breast in 7 studies
Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 9.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 9.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 7.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "The purpose of this randomized, placebo-controlled, double-blind study was to investigate the preventive effect of oral administration of celecoxib (CLX) on the acute radiation- induced skin toxicity in patients with breast cancer." | 5.27 | Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer. ( Danesh, B; Ghasemi, A; Hosseinimehr, SJ; Yazdani-Charati, J, 2018) |
| "In a single-centre double-blind phase II study, thirty-seven breast cancer patients were randomised to receive either pre-operative celecoxib (400 mg) twice daily for two to three weeks (n = 22) or a placebo according to the same schedule (n = 15)." | 5.17 | A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. ( Ayoubi, T; Blok, MJ; Brandão, RD; de Vries, B; Hupperets, PS; Keymeulen, K; Lindsey, P; Smeets, HJ; Tjan-Heijnen, VC; Van de Vijver, KK; van Elssen, CH; Veeck, J, 2013) |
| "NAF and plasma samples were collected before, 2 weeks after taking celecoxib 400 mg bid, and two weeks after washout from 26 women who were at increased breast cancer risk." | 3.73 | Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer. ( Flynn, JT; Hewett, JE; Qin, W; Sauter, ER; Schlatter, L, 2006) |
| "However, not all breast cancer patients respond to aromatase inhibitors (AI), and many patients become unresponsive or relapse." | 2.76 | Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation. ( Chan, MS; Chanplakorn, N; Chanplakorn, P; Chow, LW; Ono, K; Sasano, H; Suzuki, T; Wang, L; Wing, L; Yiu, CC, 2011) |
| "CDH11 expressing basal-like breast carcinomas and other CDH11 expressing malignancies exhibit poor prognosis." | 1.40 | Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies. ( Anastasiadis, PZ; Assefnia, S; Brenner, M; Brown, ML; Byers, SW; Dakshanamurthy, S; Foley, DW; Guidry Auvil, JM; Haigh, D; Hampel, C; Kallakury, B; Shapiro, L; Uren, A, 2014) |
| "Celecoxib is a nonsteroidal anti-inflammatory drug that selectively inhibits COX-2." | 1.36 | Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model. ( Buttars, S; Done, SJ; Tran-Thanh, D; Wen, Y; Wilson, C, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghasemi, A | 1 |
| Danesh, B | 1 |
| Yazdani-Charati, J | 1 |
| Hosseinimehr, SJ | 1 |
| Brandão, RD | 1 |
| Veeck, J | 1 |
| Van de Vijver, KK | 1 |
| Lindsey, P | 1 |
| de Vries, B | 1 |
| van Elssen, CH | 1 |
| Blok, MJ | 1 |
| Keymeulen, K | 1 |
| Ayoubi, T | 1 |
| Smeets, HJ | 1 |
| Tjan-Heijnen, VC | 1 |
| Hupperets, PS | 1 |
| Assefnia, S | 1 |
| Dakshanamurthy, S | 1 |
| Guidry Auvil, JM | 1 |
| Hampel, C | 1 |
| Anastasiadis, PZ | 1 |
| Kallakury, B | 1 |
| Uren, A | 1 |
| Foley, DW | 1 |
| Brown, ML | 1 |
| Shapiro, L | 1 |
| Brenner, M | 1 |
| Haigh, D | 1 |
| Byers, SW | 1 |
| Tran-Thanh, D | 1 |
| Buttars, S | 1 |
| Wen, Y | 1 |
| Wilson, C | 1 |
| Done, SJ | 1 |
| Bundred, NJ | 1 |
| Cramer, A | 1 |
| Morris, J | 1 |
| Renshaw, L | 1 |
| Cheung, KL | 1 |
| Flint, P | 1 |
| Johnson, R | 1 |
| Young, O | 1 |
| Landberg, G | 1 |
| Grassby, S | 1 |
| Turner, L | 1 |
| Baildam, A | 1 |
| Barr, L | 1 |
| Dixon, JM | 1 |
| Chanplakorn, N | 1 |
| Chanplakorn, P | 1 |
| Suzuki, T | 1 |
| Ono, K | 1 |
| Wang, L | 1 |
| Chan, MS | 1 |
| Wing, L | 1 |
| Yiu, CC | 1 |
| Chow, LW | 1 |
| Sasano, H | 1 |
| Sauter, ER | 1 |
| Qin, W | 1 |
| Schlatter, L | 1 |
| Hewett, JE | 1 |
| Flynn, JT | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Controlled Phase II Trial of Pre-operative Celecoxib Treatment in Breast Cancer[NCT01695226] | Phase 2 | 0 participants | Interventional | 2004-02-29 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for celecoxib and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Randomized Double-blind Placebo-controlled Trial of Celecoxib for the Prevention of Skin Toxicity in Patients Receiving Radiation Therapy for Breast Cancer.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Breast Neoplasms; Carcinoma, Ductal, Breast; Celecox | 2018 |
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer.
Topics: Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Celecoxib; Cyclo | 2013 |
Cyclooxygenase-2 inhibition does not improve the reduction in ductal carcinoma in situ proliferation with aromatase inhibitor therapy: results of the ERISAC randomized placebo-controlled trial.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aromatase Inhibitors; Bre | 2010 |
Increased 5α-reductase type 2 expression in human breast carcinoma following aromatase inhibitor therapy: the correlation with decreased tumor cell proliferation.
Topics: 17-Hydroxysteroid Dehydrogenases; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androstadienes; Antineoplas | 2011 |
3 other studies available for celecoxib and Carcinoma, Ductal, Breast
| Article | Year |
|---|---|
Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.
Topics: Animals; Antibodies, Monoclonal; Apoptosis; Arthritis, Rheumatoid; Blotting, Western; Breast Neoplas | 2014 |
Cyclooxygenase-2 inhibition for the prophylaxis and treatment of preinvasive breast cancer in a her-2/neu mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, B | 2010 |
Celecoxib decreases prostaglandin E2 concentrations in nipple aspirate fluid from high risk postmenopausal women and women with breast cancer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Body Fluids; Breast Neoplasms; Car | 2006 |